NEW YORK ( TheStreet) -- CHANGE IN RATINGS
(AMGN - Get Report)
rated new Buy at Stifel Nicolaus. $68 price target. Company has the only major new product among its peers.
(CE - Get Report)
upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down.
(CELG - Get Report)
rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects.
(GILD - Get Report)
rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations.
(IDXX - Get Report)
rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential.
Skilled Healthcare Group
upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2.
(TEVA - Get Report)
upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010.
downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil.
was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.
STOCK COMMENTS / EPS CHANGES
estimates, target increased through 2011 at Citigroup. Company boosted guidance at its midquarter update. Buy rating and new $36 price target.
estimates, target lowered at UBS. Estimates cut through 2011. Cable CapEx spending could be slowing down, along with the broader economy. Neutral rating and new $9 price target.
numbers boosted at Citigroup. Shares of AYE now seen reaching $24, according to Citigroup. Estimates also upped, as the company is cutting costs and should see higher regulated earnings. Hold rating.
numbers raised at UBS. Shares of CCE now seen reaching $34, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating.
Chesapeake Midstream Partners
estimates cut at Barclays. 2011 EPS estimate lowered to $1.51, 2010 held at $1.05. Chesapeake Midstream reported second-quarter results in line, Barclays said. Maintain Overweight rating and $26 target.
target upped to $52 at Keybanc. Company held an upbeat investor meeting, and the Hub channel remains on track for launch. Buy rating.
Las Vegas Sands
numbers raised at JP Morgan. Shares of LVS now seen reaching $36, according to JP Morgan. Estimates also increased, given better results in Singapore. Overweight rating.